1932

Abstract

Coenzyme Q (CoQ) is an essential lipid of cells present in all cellular compartments. The functions of CoQ in mitochondrial respiration and as an antioxidant are established, although the lipid likely has additional, presently unknown, roles. While the therapeutic utility of CoQ supplements is recognized in the rare cases of primary CoQ deficiencies, a potential role for CoQ supplements in cardiovascular disease, particularly heart failure, has also been studied for over 40 years. This review summarizes our current knowledge in these areas derived from animal studies and human trials. Current evidence for a benefit of CoQ supplements in diseases other than primary CoQ deficiencies is insufficient.

Loading

Article metrics loading...

/content/journals/10.1146/annurev-nutr-071714-034258
2015-07-17
2024-05-23
Loading full text...

Full text loading...

/deliver/fulltext/nutr/35/1/annurev-nutr-071714-034258.html?itemId=/content/journals/10.1146/annurev-nutr-071714-034258&mimeType=html&fmt=ahah

Literature Cited

  1. Åberg F, Appelkvist E-L, Dallner G, Ernster L. 1.  1992. Distribution and redox state of ubiquinones in rat and human tissues. Arch. Biochem. Biophys. 295:230–34 [Google Scholar]
  2. Alam SS, Nambudiri AM, Rudney H. 2.  1975. J-Hydroxybenzoate: polyprenyl transferase and the prenylation of 4-aminobenzoate in mammalian tissues. Arch. Biochem. Biophys. 171:183–90 [Google Scholar]
  3. Allan CM, Awad AM, Johnson JS, Shirasaki DI, Wang C. 2a.  et al. 2010. Identification of Coq11, a new coenzyme Q biosynthetic protein in the CoQ-synthome in Saccharomyces cerevisiae. J. Biol. Chem. 290:7517–34 [Google Scholar]
  4. Ashraf S, Gee HY, Woerner S, Xie LX, Vega-Warner V. 3.  et al. 2013. ADCK4 mutations promote steroid-resistant nephrotic syndrome through CoQ10 biosynthesis disruption. J. Clin. Investig. 123:5179–89 [Google Scholar]
  5. Banach M, Serban C, Sahebkar A, Ursoniu S, Rysz J. 4.  et al. 2015. Effects of coenzyme Q10 on statin-induced myopathy: a meta-analysis of randomized controlled trials. Mayo Clin. Proc. 90:24–34 [Google Scholar]
  6. Barry E, Alvarez JA, Scully RE, Miller TL, Lipshultz SE. 5.  2007. Anthracycline-induced cardiotoxicity: course, pathophysiology, prevention and management. Expert Opin. Pharmacother. 8:1039–58 [Google Scholar]
  7. Barshop BA, Gangoiti JA. 6.  2007. Analysis of coenzyme Q in human blood and tissues. Mitochondrion 7:Suppl.S89–93 [Google Scholar]
  8. Battino M, Gorini A, Villa RF, Genova ML, Bovina C. 7.  et al. 1995. Coenzyme Q content in synaptic and non-synaptic mitochondria from different brain regions in the ageing rat. Mech. Ageing Dev. 78:173–87 [Google Scholar]
  9. Beal MF, Oakes D, Shoulson I, Henchcliffe C, Galpern WR. 8.  et al. 2014. A randomized clinical trial of high-dosage coenzyme Q10 in early Parkinson disease: no evidence of benefit. JAMA Neurol. 71:543–52 [Google Scholar]
  10. Bech O, Sørensen J, Jensen M, Diamant B, Steiness E. 9.  1990. Effects of long-term coenzyme Q10 and captopril treatment on survival and functional capacity in rats with experimentally induced heart infarction. J. Pharmacol. Exp. Ther. 255:346–50 [Google Scholar]
  11. Belardinelli R, Muçaj A, Lacalaprice F, Solenghi M, Principi F. 10.  et al. 2005. Coenzyme Q10 improves contractility of dysfunctional myocardium in chronic heart failure. Biofactors 25:137–45 [Google Scholar]
  12. Belardinelli R, Tiano L, Littarru GP. 11.  2008. Oxidative stress, endothelial function and coenzyme Q10. Biofactors 32:129–33 [Google Scholar]
  13. Bentinger M, Dallner G, Chojnacki T, Swiezewska E. 12.  2003. Distribution and breakdown of labeled coenzyme Q10 in rat. Free Radic. Biol. Med. 34:563–75 [Google Scholar]
  14. Bentinger M, Tekle M, Dallner G, Brismar K, Gustafsson JA. 13.  et al. 2012. Influence of liver-X-receptor on tissue cholesterol, coenzyme Q and dolichol content. Mol. Membr. Biol. 29:299–308 [Google Scholar]
  15. Berman M, Erman A, Ben-Gal T, Dvir D, Georghiou GP. 14.  et al. 2004. Coenzyme Q10 in patients with end-stage heart failure awaiting cardiac transplantation: a randomized, placebo-controlled study. Clin. Cardiol. 27:295–99 [Google Scholar]
  16. Bertazzoli C, Sala L, Ballerini L, Watanabe T, Folkers K. 15.  1976. Effect of adriamycin on the activity of the succinate dehydrogenase-coenzyme Q10 reductase of the rabbit myocardium. Res. Commun. Chem. Pathol. Pharmacol. 15:797–800 [Google Scholar]
  17. Beyer RE, Burnett BA, Cartwright KJ, Edington DW, Falzon MJ. 16.  et al. 1985. Tissue coenzyme Q (ubiquinone) and protein concentrations over the life span of the laboratory rat. Mech. Ageing Dev. 32:267–81 [Google Scholar]
  18. Bhagavan HN, Chopra RK. 17.  2006. Coenzyme Q10: absorption, tissue uptake, metabolism and pharmacokinetics. Free Radic. Res. 40:445–53 [Google Scholar]
  19. Bhagavan HN, Chopra RK, Craft NE, Chitchumroonchokchai C, Failla ML. 18.  2007. Assessment of coenzyme Q10 absorption using an in vitro digestion-Caco-2 cell model. Int. J. Pharm. 333:112–17 [Google Scholar]
  20. Bogsrud MP, Langslet G, Ose L, Arnesen KE, Sm Stuen MC. 19.  et al. 2013. No effect of combined coenzyme Q10 and selenium supplementation on atorvastatin-induced myopathy. Scand. Cardiovasc. J. 47:80–87 [Google Scholar]
  21. Bookstaver DA, Burkhalter NA, Hatzigeorgiou C. 20.  2012. Effect of coenzyme Q10 supplementation on statin-induced myalgias. Am. J. Cardiol. 110:526–29 [Google Scholar]
  22. Bowry VW, Ingold KU, Stocker R. 21.  1992. Vitamin E in human low-density lipoprotein. When and how this antioxidant becomes a pro-oxidant. Biochem. J. 288:341–44 [Google Scholar]
  23. Braunwald E. 22.  2008. Biomarkers in heart failure. N. Engl. J. Med. 358:2148–59 [Google Scholar]
  24. Bui AL, Horwich TB, Fonarow GC. 23.  2011. Epidemiology and risk profile of heart failure. Nat. Rev. Cardiol. 8:30–41 [Google Scholar]
  25. Caso G, Kelly P, McNurlan MA, Lawson WE. 24.  2007. Effect of coenzyme Q10 on myopathic symptoms in patients treated with statins. Am. J. Cardiol. 99:1409–12 [Google Scholar]
  26. Chai W, Novotny R, Maskarinec G, Marchand LL, Franke AA, Cooney RV. 25.  2014. Serum coenzyme Q10, α-tocopherol, γ-tocopherol, and C-reactive protein levels and body mass index in adolescent and premenopausal females. J. Am. Coll. Nutr. 33:192–97 [Google Scholar]
  27. Chello M, Mastroroberto P, Romano R, Bevacqua E, Pantaleo D. 26.  et al. 1994. Protection by coenzyme Q10 from myocardial reperfusion injury during coronary artery bypass grafting. Ann. Thorac. Surg. 58:1427–32 [Google Scholar]
  28. Chen YF, Lin YT, Wu SC. 27.  1994. Effectiveness of coenzyme Q10 on myocardial preservation during hypothermic cardioplegic arrest. J. Thorac. Cardiovasc. Surg. 107:242–47 [Google Scholar]
  29. Choe JY, Combs AB, Folkers K. 28.  1979. Prevention by coenzyme Q10 of the electrocardiographic changes induced by adriamycin in rats. Res. Commun. Chem. Pathol. Pharmacol. 23:199–202 [Google Scholar]
  30. Choe JY, Combs AB, Saji S, Folkers K. 29.  1979. Study of the combined and separate administration of doxorubicin and coenzyme Q10 on mouse cardiac enzymes. Res. Commun. Chem. Pathol. Pharmacol. 24:595–98 [Google Scholar]
  31. Chopra RK, Goldman R, Sinatra ST, Bhagavan HN. 30.  1997. Relative bioavailability of coenzyme Q10 formulations in human subjects. Int. J. Vitam. Nutr. Res. 68:109–13 [Google Scholar]
  32. Conklin KA. 31.  2005. Coenzyme Q10 for prevention of anthracycline-induced cardiotoxicity. Integr. Cancer Ther. 4:110–30 [Google Scholar]
  33. Cortes EP, Gupta M, Chou C, Amin VC, Folkers K. 32.  1978. Adriamycin cardiotoxicity: early detection by systolic time interval and possible prevention by coenzyme Q10. Cancer Treat. Rep. 62:887–91 [Google Scholar]
  34. Cowie MR, Wood DA, Coats AJ, Thompson SG, Suresh V. 33.  et al. 2000. Survival of patients with a new diagnosis of heart failure: a population based study. Heart 83:505–10 [Google Scholar]
  35. Crane F, Hatefi Y, Lester R, Widmer C. 34.  1957. Isolation of a quinone from beef heart mitochondria. Biochim. Biophys. Acta 25:220–21 [Google Scholar]
  36. Crane F, Sun I, Clark M, Grebing C, Löw H. 35.  1985. Transplasma-membrane redox systems in growth and development. Biochim. Biophys. Acta 811:233–64 [Google Scholar]
  37. Crestanello JA, Doliba NM, Doliba NM, Babsky AM, Niborii K. 36.  et al. 2002. Effect of coenzyme Q10 supplementation on mitochondrial function after myocardial ischemia reperfusion. J. Surg. Res. 102:221–28 [Google Scholar]
  38. Crestanello JA, Kamelgard J, Lingle DM, Mortensen SA, Rhode M, Whitman GJ. 37.  1996. Elucidation of a tripartite mechanism underlying the improvement in cardiac tolerance to ischemia by coenzyme Q10 pretreatment. J. Thorac. Cardiovasc. Surg. 111:443–50 [Google Scholar]
  39. Dadabayev AR, Yin G, Latchoumycandane C, McIntyre TM, Lesnefsky EJ, Penn MS. 38.  2014. Apolipoprotein A1 regulates coenzyme Q10 absorption and mitochondrial function and infarct size in a mouse model of myocardial infarction. J. Nutr. 144:1030–36 [Google Scholar]
  40. Dallner G, Stocker R. 39.  2010. Coenzyme Q10. Encyclopedia of Dietary Supplements P Coates, JM Betz, MR Blackman, G Craff, MM Levine, et al. 157–65 New York: Informa Healthc. [Google Scholar]
  41. De Cabo R, Cabello R, Rios M, Lopez-Lluch G, Ingram DK. 40.  et al. 2004. Calorie restriction attenuates age-related alterations in the plasma membrane antioxidant system in rat liver. Exp. Gerontol. 39:297–304 [Google Scholar]
  42. Deichmann RE, Lavie CJ, Dornelles AC. 41.  2012. Impact of coenzyme Q-10 on parameters of cardiorespiratory fitness and muscle performance in older athletes taking statins. Phys. Sportsmed. 40:88–95 [Google Scholar]
  43. Devun F, Walter L, Belliere J, Cottet-Rousselle C, Leverve X, Fontaine E. 42.  2010. Ubiquinone analogs: a mitochondrial permeability transition pore-dependent pathway to selective cell death. PLOS ONE 5:e11792 [Google Scholar]
  44. Doimo M, Desbats MA, Cerqua C, Cassina M, Trevisson E, Salviati L. 43.  2014. Genetics of coenzyme Q10 deficiency. Mol. Syndromol. 5:156–62 [Google Scholar]
  45. Domae N, Sawada H, Matsuyama E, Konishi T, Uchino H. 44.  1981. Cardiomyopathy and other chronic toxic effects induced in rabbits by doxorubicin and possible prevention by coenzyme Q10. Cancer Treat. Rep. 65:79–91 [Google Scholar]
  46. Emmanuele V, Lopez LC, Berardo A, Naini A, Tadesse S. 45.  et al. 2012. Heterogeneity of coenzyme Q10 deficiency: patient study and literature review. Arch. Neurol. 69:978–83 [Google Scholar]
  47. Failla ML, Chitchumroonchokchai C, Aoki F. 46.  2014. Increased bioavailability of ubiquinol compared to that of ubiquinone is due to more efficient micellarization during digestion and greater GSH-dependent uptake and basolateral secretion by Caco-2 cells. J. Agric. Food Chem. 62:7174–82 [Google Scholar]
  48. 47. Fatkin D, Csanz Cardiac Genetic Diseases Council Writing Group members 2011. Guidelines for the diagnosis and management of familial dilated cardiomyopathy. Heart Lung Circ. 20:691–93 [Google Scholar]
  49. Fedacko J, Pella D, Fedackova P, Hanninen O, Tuomainen P. 48.  et al. 2013. Coenzyme Q10 and selenium in statin-associated myopathy treatment. Can. J. Physiol. Pharmacol. 91:165–70 [Google Scholar]
  50. Fernández-Ayala DJ, Brea-Calvo G, López-Lluch G, Navas P. 49.  2005. Coenzyme Q distribution in HL-60 human cells depends on the endomembrane system. Biochim. Biophys. Acta 1713:129–37 [Google Scholar]
  51. Ferrante K, Shefner J, Zhang H, Betensky R, O'Brien M. 50.  et al. 2005. Tolerance of high-dose (3,000 mg/day) coenzyme Q10 in ALS. Neurology 65:1834–36 [Google Scholar]
  52. Flowers N, Hartley L, Todkill D, Stranges S, Rees K. 51.  2014. Co-enzyme Q10 supplementation for the primary prevention of cardiovascular disease. Cochrane Database Syst. Rev. 12:CD010405 [Google Scholar]
  53. Folkers K, Baker L, Richardson PC. 52.  1980. Biomedical and clinical research on coenzyme Q10. Biomedical and Clinical Aspects of Coenzyme Q K Folkers, Y Yamamura, Y Ito 2447–54 Amsterdam: Elsevier [Google Scholar]
  54. Folkers K, Choe JY, Combs AB. 53.  1978. Rescue by coenzyme Q10 from electrocardiographic abnormalities caused by the toxicity of adriamycin in the rat. PNAS 75:5178–80 [Google Scholar]
  55. Folkers K, Langsjoen P, Willis R, Richardson P, Xia L-J. 54.  et al. 1990. Lovastatin decreases coenzyme Q levels in humans. PNAS 87:8931–34 [Google Scholar]
  56. Folkers K, Littarru G, Ho L, Runge TM, Havanonda S, Cooley D. 55.  1970. Evidence for a deficiency of coenzyme Q10 in human heart disease. Int. Z. Vitaminforsch. 40:380–90 [Google Scholar]
  57. Folkers K, Liu M, Watanabe T, Porter TH. 56.  1977. Inhibition by adriamycin of the mitochondrial biosynthesis of coenzyme Q10 and implication for the cardiotoxicity of adriamycin in cancer patients. Biochem. Biophys. Res. Commun. 77:1536–42 [Google Scholar]
  58. Folkers K, Wolaniuk J, Simonsen R, Morishita M, Vadhanavikit S. 57.  1985. Biochemical rationale and the cardiac response of patients with muscle disease to therapy with coenzyme Q10. PNAS 82:4513–16 [Google Scholar]
  59. Fotino AD, Thompson-Paul AM, Bazzano LA. 58.  2013. Effect of coenzyme Q10 supplementation on heart failure: a meta-analysis. Am. J. Clin. Nutr. 97:268–75 [Google Scholar]
  60. Garjani A, Andalib S, Biabani S, Soraya H, Doustar Y. 59.  et al. 2011. Combined atorvastatin and coenzyme Q10 improve the left ventricular function in isoproterenol-induced heart failure in rat. Eur. J. Pharmacol. 666:135–41 [Google Scholar]
  61. Garrido-Maraver J, Cordero MD, Oropesa-Ávila M, Fernández Vega A, de la Mata M. 60.  et al. 2014. Coenzyme Q10 therapy. Mol. Syndromol. 5:187–97 [Google Scholar]
  62. Gay CA, Stocker R. 61.  2004. Simultaneous determination of coenzyme Q10, cholesterol, and major cholesterylesters in human blood plasma. Methods Enzymol. 378:162–69 [Google Scholar]
  63. Ghirlanda G, Oradei A, Manto A, Lippa S, Uccioli L. 62.  et al. 1993. Evidence of plasma CoQ10-lowering effect by HMG-CoA reductase inhibitors: a double-blind, placebo-controlled study. J. Clin. Pharmacol. 33:226–29 [Google Scholar]
  64. Gómez-Dıaz C, Villalba J, Perez-Vicente R, Crane F, Navas P. 63.  1997. Ascorbate stabilization is stimulated in ρ° HL-60 cells by CoQ10 increase at the plasma membrane. Biochem. Biophys. Res. Commun. 234:79–81 [Google Scholar]
  65. Gonzalez-Mariscal I, Garcia-Teston E, Padilla S, Martin-Montalvo A, Pomares-Viciana T. 64.  et al. 2014. Regulation of coenzyme Q biosynthesis in yeast: a new complex in the block. IUBMB Life 66:63–70 [Google Scholar]
  66. Grunler J, Parmryd I. 65.  1999. Subcellular distribution of farnesyl protein transferase in rat liver. FEBS Lett. 455:233–37 [Google Scholar]
  67. Haas RH. 66.  2007. The evidence basis for coenzyme Q therapy in oxidative phosphorylation disease. Mitochondrion 7:Suppl.S136–45 [Google Scholar]
  68. Hano O, Thompson-Gorman SL, Zweier JL, Lakatta EG. 67.  1994. Coenzyme Q10 enhances cardiac functional and metabolic recovery and reduces Ca2+ overload during postischemic reperfusion. Am. J. Physiol. 266:H2174–81 [Google Scholar]
  69. Harker-Murray AK, Tajik AJ, Ishikura F, Meyer D, Burnett JC, Redfield MM. 68.  2000. The role of coenzyme Q10 in the pathophysiology and therapy of experimental congestive heart failure in the dog. J. Card. Fail. 6:233–42 [Google Scholar]
  70. He CH, Xie LX, Allan CM, Tran UC, Clarke CF. 69.  2014. Coenzyme Q supplementation or over-expression of the yeast Coq8 putative kinase stabilizes multi-subunit Coq polypeptide complexes in yeast coq null mutants. Biochim. Biophys. Acta 1841:630–44 [Google Scholar]
  71. Ho MJ, Bellusci A, Wright JM. 70.  2009. Blood pressure lowering efficacy of coenzyme Q10 for primary hypertension. Cochrane Database Syst. Rev. 4:CD007435 [Google Scholar]
  72. Hofman-Bang C, Rehnqvist N, Swedberg K, Wiklund I, Åström H. 71.  1995. Coenzyme Q10 as an adjunctive in the treatment of chronic congestive heart failure. J. Card. Fail. 1:101–7 [Google Scholar]
  73. Hunt SA, Abraham WT, Chin MH, Feldman AM, Francis GS. 72.  et al. 2005. ACC/AHA 2005 guideline update for the diagnosis and management of chronic heart failure in the adult. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Update the 2001 Guidelines for the Evaluation and Management of Heart Failure): developed in collaboration with the American College of Chest Physicians and the International Society for Heart and Lung Transplantation: endorsed by the Heart Rhythm Society. Circulation 112:e154–235 [Google Scholar]
  74. Iarussi D, Auricchio U, Agretto A, Murano A, Giuliano M. 73.  et al. 1994. Protective effect of coenzyme Q10 on anthracyclines cardiotoxicity: control study in children with acute lymphoblastic leukemia and non-Hodgkin lymphoma. Mol. Aspects Med. 15:Suppl.s207–12 [Google Scholar]
  75. Ivanov AV, Gorodetskaya EA, Kalenikova EI, Medvedev OS. 74.  2013. Single intravenous injection of coenzyme Q10 protects the myocardium after irreversible ischemia. Bull. Exp. Biol. Med. 155:771–74 [Google Scholar]
  76. Jeya M, Moon HJ, Lee JL, Kim IW, Lee JK. 75.  2010. Current state of coenzyme Q10 production and its applications. Appl. Microbiol. Biotechnol. 85:1653–63 [Google Scholar]
  77. Jin G, Kubo H, Kashiba M, Horinouchi R, Hasegawa M. 76.  et al. 2008. Saposin B is a human coenzyme Q10-binding/transfer protein. J. Clin. Biochem. Nutr. 42:167–74 [Google Scholar]
  78. Judy WV, Stogsdill WW, Folkers K. 77.  1993. Myocardial preservation by therapy with coenzyme Q10 during heart surgery. Clin. Investig. 71:S155–61 [Google Scholar]
  79. Kalén A, Appelkvist EL, Dallner G. 78.  1989. Age-related changes in the lipid compositions of rat and human tissues. Lipids 24:579–84 [Google Scholar]
  80. Kalén A, Appelkvist EL, Chojnacki T, Dallner G. 79.  1990. Nonaprenyl-4-hydroxybenzoate transferase, an enzyme involved in ubiquinone biosynthesis, in the endoplasmic reticulum-Golgi system of rat liver. J. Biol. Chem. 265:1158–64 [Google Scholar]
  81. Kamei M, Fujita T, Kanbe T, Sasaki K, Oshiba K. 80.  et al. 1985. The distribution and content of ubiquinone in foods. Int. J. Vitam. Nutr. Res. 56:57–63 [Google Scholar]
  82. Kanji S, Seely D, Yazdi F, Tetzlaff J, Singh K. 81.  et al. 2012. Interactions of commonly used dietary supplements with cardiovascular drugs: a systematic review. Syst. Rev. 1:26–42 [Google Scholar]
  83. Katayama K, Fujita T. 82.  1972. Studies on lymphatic absorption of 1′,2′-(3 H)-coenzyme Q 10 in rats. Chem. Pharm. Bull. (Tokyo) 20:2585–92 [Google Scholar]
  84. Keogh A, Fenton S, Leslie C, Aboyoun C, Macdonald P. 83.  et al. 2003. Randomised double-blind, placebo-controlled trial of coenzyme Q10 therapy in class II and III systolic heart failure. Heart Lung Circ. 12:135–41 [Google Scholar]
  85. Khatta M, Alexander BS, Krichten CM, Fisher ML, Freudenberger R. 84.  et al. 2000. The effect of coenzyme Q10 in patients with congestive heart failure. Ann. Intern. Med. 132:636–40 [Google Scholar]
  86. Khorrami A, Garjani A, Ghanbarzadeh S, Andalib S. 85.  2014. Reduction of coenzyme Q10 content: a possible effect of isoproterenol on heart failure and myocardial infarction in rat. Drug Res. (Stuttg.) 64:177–81 [Google Scholar]
  87. Kocharian A, Shabanian R, Rafiei-Khorgami M, Kiani A, Heidari-Bateni G. 86.  2009. Coenzyme Q10 improves diastolic function in children with idiopathic dilated cardiomyopathy. Cardiol. Young 19:501–6 [Google Scholar]
  88. Konishi T, Nakamura Y, Konishi T, Kawai C. 87.  1985. Improvement in recovery of left ventricular function during reperfusion with coenzyme Q10 in isolated working rat heart. Cardiovasc. Res. 19:38–43 [Google Scholar]
  89. Krisans SK. 88.  1996. Cell compartmentalization of cholesterol biosynthesis. Ann. N. Y. Acad. Sci. 804:142–64 [Google Scholar]
  90. Krum H, Jelinek MV, Stewart S, Sindone A, Atherton JJ. 89.  et al. 2006. Guidelines for the prevention, detection and management of people with chronic heart failure in Australia 2006. Med. J. Aust. 185:549–57 [Google Scholar]
  91. Kuklinski B, Weissenbacher E, Fahnrich A. 90.  1994. Coenzyme Q10 and antioxidants in acute myocardial infarction. Mol. Aspects Med. 15:Suppl.s143–47 [Google Scholar]
  92. Langsjoen PH, Langsjoen PH, Folkers K. 91.  1993. Isolated diastolic dysfunction of the myocardium and its response to CoQ10 treatment. Clin. Investig. 71:S140–44 [Google Scholar]
  93. Langsjoen PH, Vadhanavikit S, Folkers K. 92.  1985. Effective treatment with coenzyme Q10 of patients with chronic myocardial disease. Drugs Exp. Clin. Res. 11:577–79 [Google Scholar]
  94. Langsjoen PH, Vadhanavikit S, Folkers K. 93.  1985. Response of patients in classes III and IV of cardiomyopathy to therapy in a blind and crossover trial with coenzyme Q10. PNAS 82:4240–44 [Google Scholar]
  95. Lass A, Kwong L, Sohal RS. 94.  1999. Mitochondrial coenzyme Q content and aging. Biofactors 9:199–205 [Google Scholar]
  96. Lee BJ, Huang YC, Chen SJ, Lin PT. 95.  2012. Coenzyme Q10 supplementation reduces oxidative stress and increases antioxidant enzyme activity in patients with coronary artery disease. Nutrition 28:250–55 [Google Scholar]
  97. Lee BJ, Tseng YF, Yen CH, Lin PT. 96.  2013. Effects of coenzyme Q10 supplementation (300 mg/day) on antioxidation and anti-inflammation in coronary artery disease patients during statins therapy: a randomized, placebo-controlled trial. Nutr. J. 12:142 [Google Scholar]
  98. Legha SS, Wang YM, Mackay B, Ewer M, Hortobagyi GN. 97.  et al. 1982. Clinical and pharmacologic investigation of the effects of α-tocopherol on adriamycin cardiotoxicity. Ann. N. Y. Acad. Sci. 393:411–18 [Google Scholar]
  99. Levy HB, Kohlhaas HK. 98.  2006. Considerations for supplementing with coenzyme Q10 during statin therapy. Ann. Pharmacother. 40:290–94 [Google Scholar]
  100. Lipinski MJ, Cauthen CA, Biondi-Zoccai GG, Abbate A, Vrtovec B. 99.  et al. 2009. Meta-analysis of randomized controlled trials of statins versus placebo in patients with heart failure. Am. J. Cardiol. 104:1708–16 [Google Scholar]
  101. Liu G, Zheng XX, Xu YL, Lu J, Hui RT, Huang XH. 100.  2014. Effects of lipophilic statins for heart failure: a meta-analysis of 13 randomised controlled trials. Heart Lung Circ. 23:970–77 [Google Scholar]
  102. Lonnrot K, Tolvanen JP, Porsti I, Ahola T, Hervonen A, Alho H. 101.  1999. Coenzyme Q10 supplementation and recovery from ischemia in senescent rat myocardium. Life Sci. 64:315–23 [Google Scholar]
  103. López LC, Schuelke M, Quinzii CM, Kanki T, Rodenburg RJ. 102.  et al. 2006. Leigh syndrome with nephropathy and CoQ10 deficiency due to decaprenyl diphosphate synthase subunit 2 (PDSS2) mutations. Am. J. Hum. Genet. 79:1125–29 [Google Scholar]
  104. Macdonald PS. 103.  2010. Heart failure with preserved ejection fraction–coming to terms with an oxymoron. Med. J. Aust. 192:4–5 [Google Scholar]
  105. Madmani ME, Yusuf Solaiman A, Tamr Agha K, Madmani Y, Shahrour Y. 104.  et al. 2014. Coenzyme Q10 for heart failure. Cochrane Database Syst. Rev. 6:CD008684 [Google Scholar]
  106. Makhija N, Sendasgupta C, Kiran U, Lakshmy R, Hote MP. 105.  et al. 2008. The role of oral coenzyme Q10 in patients undergoing coronary artery bypass graft surgery. J. Cardiothorac. Vasc. Anesth. 22:832–39 [Google Scholar]
  107. Marbois B, Xie LX, Choi S, Hirano K, Hyman K, Clarke CF. 106.  2010. para-Aminobenzoic acid is a precursor in coenzyme Q6 biosynthesis in Saccharomyces cerevisiae. J. Biol. Chem. 285:27827–38 [Google Scholar]
  108. Marcoff L, Thompson PD. 107.  2007. The role of coenzyme Q10 in statin-associated myopathy: a systematic review. J. Am. Coll. Cardiol. 49:2231–37 [Google Scholar]
  109. McMurray JJ, Dunselman P, Wedel H, Cleland JG, Lindberg M. 108.  et al. 2010. Coenzyme Q10, rosuvastatin, and clinical outcomes in heart failure: a pre-specified substudy of CORONA (Controlled Rosuvastatin Multinational Study in Heart Failure). J. Am. Coll. Cardiol. 56:1196–204 [Google Scholar]
  110. McMurray JJ, Packer M, Desai AS, Gong J, Lefkowitz MP. 109.  et al. 2014. Angiotensin-neprilysin inhibition versus enalapril in heart failure. N. Engl. J. Med. 371:993–1004 [Google Scholar]
  111. Miles MV. 110.  2007. The uptake and distribution of coenzyme Q10. Mitochondrion 7:Suppl.S72–77 [Google Scholar]
  112. Mills E, Wu P, Johnston BC, Gallicano K, Clarke M, Guyatt G. 111.  2005. Natural health product–drug interactions: a systematic review of clinical trials. Ther. Drug Monit. 27:549–57 [Google Scholar]
  113. Mischley LK, Allen J, Bradley R. 112.  2012. Coenzyme Q10 deficiency in patients with Parkinson's disease. J. Neurol. Sci. 318:72–75 [Google Scholar]
  114. Mitchell P. 113.  1975. Protonmotive redox mechanism of the cytochrome bc1 complex in the respiratory chain: protonmotive ubiquinone cycle. FEBS Lett. 56:1–6 [Google Scholar]
  115. Mohr D, Umeda Y, Redgrave TG, Stocker R. 114.  1999. Antioxidant defenses in rat intestine and mesenteric lymph. Redox Rep. 4:79–87 [Google Scholar]
  116. Molyneux SL, Young JM, Florkowski CM, Lever M, George PM. 115.  2008. Coenzyme Q10: Is there a clinical role and a case for measurement?. Clin. Biochem. Rev. 29:71–82 [Google Scholar]
  117. Moreno-Fernández AM, Cordero MD, Garrido-Maraver J, Alcocer-Gómez E, Casas-Barquero N. 116.  et al. 2012. Oral treatment with amitriptyline induces coenzyme Q deficiency and oxidative stress in psychiatric patients. J. Psychiatr. Res. 46:341–45 [Google Scholar]
  118. Morisco C, Nappi A, Argenziano L, Sarno D, Fonatana D. 117.  et al. 1994. Noninvasive evaluation of cardiac hemodynamics during exercise in patients with chronic heart failure: effects of short-term coenzyme Q10 treatment. Mol. Aspects Med. 15:Suppl.s155–63 [Google Scholar]
  119. Morisco C, Trimarco B, Condorelli M. 118.  1993. Effect of coenzyme Q10 therapy in patients with congestive heart failure: a long-term multicenter randomized study. Clin. Investig. 71:S134–36 [Google Scholar]
  120. Morita K, Ihnken K, Buckberg GD, Young HH. 119.  1995. Studies of hypoxemic/reoxygenation injury: without aortic clamping. VII. Counteraction of oxidant damage by exogenous antioxidants: coenzyme Q10. J. Thorac. Cardiovasc. Surg. 110:1221–27 [Google Scholar]
  121. Mortensen SA, Rosenfeldt F, Kumar A, Dolliner P, Filipiak KJ. 120.  et al. 2014. The effect of coenzyme Q10 on morbidity and mortality in chronic heart failure. Results from Q-SYMBIO: a randomized double-blind trial. JACC Heart Fail. 2:641–49 [Google Scholar]
  122. Mortensen SA, Vadhanavikit S, Baandrup U, Folkers K. 121.  1985. Long-term coenzyme Q10 therapy: a major advance in the management of resistant myocardial failure. Drugs Exp. Clin. Res. 11:581–93 [Google Scholar]
  123. Mugoni V, Postel R, Catanzaro V, De Luca E, Turco E. 122.  et al. 2013. Ubiad1 is an antioxidant enzyme that regulates eNOS activity by CoQ10 synthesis. Cell 152:504–18 [Google Scholar]
  124. Munkholm H, Hansen HH, Rasmussen K. 123.  1999. Coenzyme Q10 treatment in serious heart failure. Biofactors 9:285–89 [Google Scholar]
  125. Murphy CJ, Oudit GY. 124.  2010. Iron-overload cardiomyopathy: pathophysiology, diagnosis, and treatment. J. Card. Fail. 16:888–900 [Google Scholar]
  126. Muthukumaran K, Leahy S, Harrison K, Sikorska M, Sandhu JK. 125.  et al. 2014. Orally delivered water soluble coenzyme Q10 (Ubisol-Q10) blocks on-going neurodegeneration in rats exposed to paraquat: potential for therapeutic application in Parkinson's disease. BMC Neurosci. 15:21–32 [Google Scholar]
  127. Nagai S, Miyazaki Y, Ogawa K, Satake T, Sugiyama S, Ozawa T. 126.  1985. The effect of coenzyme Q10 on reperfusion injury in canine myocardium. J. Mol. Cell. Cardiol. 17:873–84 [Google Scholar]
  128. Nakamura T, Ohno T, Hamamura K, Sato T. 127.  1999. Metabolism of coenzyme Q10: biliary and urinary excretion study in guinea pigs. Biofactors 9:111–19 [Google Scholar]
  129. 128. Natl. Inst. Health 2014. Coenzyme Q10 (CoQ10): What You Need to Know. Bethesda, MD: Natl. Cent. Complement. Integr. Health http://nccam.nih.gov/health/supplements/coq10 [Google Scholar]
  130. Nordman T, Xia L, Björkhem-Bergman L, Damdimopoulos A, Nalvarte I. 129.  et al. 2003. Regeneration of the antioxidant ubiquinol by lipoamide dehydrogenase, thioredoxin reductase and glutathione reductase. Biofactors 18:45–50 [Google Scholar]
  131. Ogasahara S, Engel AG, Frens D, Mack D. 130.  1989. Muscle coenzyme Q deficiency in familial mitochondrial encephalomyopathy. PNAS 86:2379–82 [Google Scholar]
  132. Ohhara H, Kanaide H, Yoshimura R, Okada M, Nakamura M. 131.  1981. A protective effect of coenzyme Q10 on ischemia and reperfusion of the isolated perfused rat heart. J. Mol. Cell. Cardiol. 13:65–74 [Google Scholar]
  133. Okuma K, Ota K. 132.  1986. The effect of coenzyme Q10 on ECG changes induced by doxorubicin (Adriamycin). Biomedical and Clinical Aspects of Coenzyme Q K Folkers, Y Yamamura 5247–56 Amsterdam: Elsevier [Google Scholar]
  134. Papucci L, Schiavone N, Witort E, Donnini M, Lapucci A. 133.  et al. 2003. Coenzyme Q10 prevents apoptosis by inhibiting mitochondrial depolarization independently of its free radical scavenging property. J. Biol. Chem. 278:28220–28 [Google Scholar]
  135. Paulus WJ, Tschope C. 134.  2013. A novel paradigm for heart failure with preserved ejection fraction: comorbidities drive myocardial dysfunction and remodeling through coronary microvascular endothelial inflammation. J. Am. Coll. Cardiol. 62:263–71 [Google Scholar]
  136. Permanetter B, Rössy W, Klein G, Weingartner F, Seidl K, Blomer H. 135.  1992. Ubiquinone (coenzyme Q10) in the long-term treatment of idiopathic dilated cardiomyopathy. Eur. Heart J. 13:1528–33 [Google Scholar]
  137. Pierrel F, Hamelin O, Douki T, Kieffer-Jaquinod S, Muhlenhoff U. 136.  et al. 2010. Involvement of mitochondrial ferredoxin and para-aminobenzoic acid in yeast coenzyme Q biosynthesis. Chem. Biol. 17:449–59 [Google Scholar]
  138. Poggesi L, Galanti G, Comeglio M, Toncelli L, Vinci M. 137.  1991. Effect of coenzyme Q10 on left ventricular function in patients with dilative cardiomyopathy: a medium-term randomized double-blind study versus placebo. Curr. Ther. Res. 49:878–86 [Google Scholar]
  139. Popov VN, Purvis AC, Skulachev VP, Wagner AM. 138.  2001. Stress-induced changes in ubiquinone concentration and alternative oxidase in plant mitochondria. Biosci. Rep. 21:369–79 [Google Scholar]
  140. Pourmoghaddas M, Rabbani M, Shahabi J, Garakyaraghi M, Khanjani R, Hedayat P. 139.  2014. Combination of atorvastatin/coenzyme Q10 as adjunctive treatment in congestive heart failure: a double-blind randomized placebo-controlled clinical trial. ARYA Atheroscler. 10:1–5 [Google Scholar]
  141. Pravst I, Žmitek K, Žmitek J. 140.  2010. Coenzyme Q10 contents in foods and fortification strategies. Crit. Rev. Food Sci. Nutr. 50:269–80 [Google Scholar]
  142. Quinzii CM, Hirano M. 141.  2011. Primary and secondary CoQ10 deficiencies in humans. Biofactors 37:361–65 [Google Scholar]
  143. Redfield MM, Jacobsen SJ, Burnett JC Jr, Mahoney DW, Bailey KR, Rodeheffer RJ. 142.  2003. Burden of systolic and diastolic ventricular dysfunction in the community: appreciating the scope of the heart failure epidemic. JAMA 289:194–202 [Google Scholar]
  144. Rengo F, Abete P, Landino P, Leosco D, Covelluzzi F. 143.  et al. 1993. Role of metabolic therapy in cardiovascular disease. Clin. Investig. 71:S124–28 [Google Scholar]
  145. Ronca-Testoni S, Zucchi R, Ronca F, Bertelli A. 144.  1992. Effect of carnitine and coenzyme Q10 on the calcium uptake in heart sarcoplasmic reticulum of rats treated with anthracyclines. Drugs Exp. Clin. Res. 18:437–42 [Google Scholar]
  146. Rosenfeldt F, Hilton D, Pepe S, Krum H. 145.  2003. Systematic review of effect of coenzyme Q10 in physical exercise, hypertension and heart failure. Biofactors 18:91–100 [Google Scholar]
  147. Rosenfeldt F, Marasco S, Lyon W, Wowk M, Sheeran F. 146.  et al. 2005. Coenzyme Q10 therapy before cardiac surgery improves mitochondrial function and in vitro contractility of myocardial tissue. J. Thorac. Cardiovasc. Surg. 129:25–32 [Google Scholar]
  148. Rosenfeldt FL, Haas SJ, Krum H, Hadj A, Ng K. 147.  et al. 2007. Coenzyme Q10 in the treatment of hypertension: a meta-analysis of the clinical trials. J. Hum. Hypertens. 21:297–306 [Google Scholar]
  149. Rosenfeldt FL, Pepe S, Ou R, Mariani JA, Rowland MA. 148.  et al. 1999. Coenzyme Q10 improves the tolerance of the senescent myocardium to aerobic and ischemic stress: studies in rats and in human atrial tissue. Biofactors 9:291–99 [Google Scholar]
  150. Rossi E, Lombardo A, Testa M, Lippa S, Oradei A. 149.  et al. 1991. Coenzyme Q10 in ischaemic cardiopathy. Biomedical and Clinical Aspects of Coenzyme Q K Folkers, Y Yamamura, GP Littarru 321–26 Amsterdam: Elsevier [Google Scholar]
  151. Rötig A, Appelkvist E-L, Geromel V, Chretien D, Kadhom N. 150.  et al. 2000. Quinone-responsive multiple respiratory-chain dysfunction due to widespread coenzyme Q10 deficiency. Lancet 356:391–95 [Google Scholar]
  152. Saito Y, Fukuhara A, Nishio K, Hayakawa M, Ogawa Y. 151.  et al. 2009. Characterization of cellular uptake and distribution of coenzyme Q10 and vitamin E in PC12 cells. J. Nutr. Biochem. 20:350–57 [Google Scholar]
  153. Sanbe A, Tanonaka K, Niwano Y, Takeo S. 152.  1994. Improvement of cardiac function and myocardial energy metabolism of rats with chronic heart failure by long-term coenzyme Q10 treatment. J. Pharmacol. Exp. Ther. 269:51–56 [Google Scholar]
  154. Sanoobar M, Eghtesadi S, Azimi A, Khalili M, Khodadadi B. 153.  et al. 2015. Coenzyme Q10 supplementation ameliorates inflammatory markers in patients with multiple sclerosis: a double blind, placebo, controlled randomized clinical trial. Nutr. Neurosci. 18:169–76 [Google Scholar]
  155. Sévin DC, Sauer U. 154.  2014. Ubiquinone accumulation improves osmotic-stress tolerance in Escherichia coli. Nat. Chem. Biol. 10:266–72 [Google Scholar]
  156. Shults CW, Flint Beal M, Song D, Fontaine D. 155.  2004. Pilot trial of high dosages of coenzyme Q10 in patients with Parkinson's disease. Exp. Neurol. 188:491–94 [Google Scholar]
  157. Shults CW, Oakes D, Kieburtz K, Beal MF, Haas R. 156.  et al. 2002. Effects of coenzyme Q10 in early Parkinson disease: evidence of slowing of the functional decline. Arch. Neurol. 59:1541–50 [Google Scholar]
  158. Sikorska M, Lanthier P, Miller H, Beyers M, Sodja C. 157.  et al. 2014. Nanomicellar formulation of coenzyme Q10 (Ubisol-Q10) effectively blocks ongoing neurodegeneration in the mouse 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine model: potential use as an adjuvant treatment in Parkinson's disease. Neurobiol. Aging 35:2329–46 [Google Scholar]
  159. Silver MA, Langsjoen PH, Szabo S, Patil H, Zelinger A. 158.  2004. Effect of atorvastatin on left ventricular diastolic function and ability of coenzyme Q10 to reverse that dysfunction. Am. J. Cardiol. 94:1306–10 [Google Scholar]
  160. Singh RB, Neki NS, Kartikey K, Pella D, Kumar A. 159.  et al. 2003. Effect of coenzyme Q10 on risk of atherosclerosis in patients with recent myocardial infarction. Mol. Cell. Biochem. 246:75–82 [Google Scholar]
  161. Singh RB, Wander GS, Rastogi A, Shukla PK, Mittal A. 160.  et al. 1998. Randomized, double-blind placebo-controlled trial of coenzyme Q10 in patients with acute myocardial infarction. Cardiovasc. Drugs Ther. 12:347–53 [Google Scholar]
  162. Skarlovnik A, Janić M, Lunder M, Turk M, Šabovič M. 161.  2014. Coenzyme Q10 supplementation decreases statin-related mild-to-moderate muscle symptoms: a randomized clinical study. Med. Sci. Monit. 20:2183–88 [Google Scholar]
  163. Sohal RS, Kamzalov S, Sumien N, Ferguson M, Rebrin I. 162.  et al. 2006. Effect of coenzyme Q10 intake on endogenous coenzyme Q content, mitochondrial electron transport chain, antioxidative defenses, and life span of mice. Free Radic. Biol. Med. 40:480–87 [Google Scholar]
  164. Somaratne JB, Berry C, McMurray JJ, Poppe KK, Doughty RN, Whalley GA. 163.  2009. The prognostic significance of heart failure with preserved left ventricular ejection fraction: a literature-based meta-analysis. Eur. J. Heart Fail. 11:855–62 [Google Scholar]
  165. Sontag TJ, Parker RS. 164.  2002. Cytochrome P450 ω-hydroxylase pathway of tocopherol catabolism. Novel mechanism of regulation of vitamin E status. J. Biol. Chem. 277:25290–96 [Google Scholar]
  166. Stewart S. 165.  2003. Prognosis of patients with heart failure compared with common types of cancer. Heart Fail. Monit. 3:87–94 [Google Scholar]
  167. Stocker R, Bowry VW, Frei B. 166.  1991. Ubiquinol-10 protects human low density lipoprotein more efficiently against lipid peroxidation than does α-tocopherol. PNAS 88:1646–50 [Google Scholar]
  168. Stocker R, Keaney Jr JF. 167.  2004. Role of oxidative modifications in atherosclerosis. Physiol. Rev. 84:1381–478 [Google Scholar]
  169. Stocker R, Pollicino C, Gay CA, Nestel P, Colquhoun D. 168.  et al. 2006. Neither plasma coenzyme Q10 concentration, nor its decline during pravastatin therapy, is linked to recurrent cardiovascular disease events: a prospective case-control study from the LIPID study. Atherosclerosis 187:198–204 [Google Scholar]
  170. Storch A, Jost WH, Vieregge P, Spiegel J, Greulich W. 169.  et al. 2007. Randomized, double-blind, placebo-controlled trial on symptomatic effects of coenzyme Q10 in Parkinson disease. Arch. Neurol. 64:938–44 [Google Scholar]
  171. Strazisar M, Fir M, Golc-Wondra A, Milivojevic L, Prosek M, Abram V. 170.  2005. Quantitative determination of coenyzme Q10 by liquid chromatography and liquid chromatography/mass spectrometry in dairy products. J. AOAC Intl. 88:1020–27 [Google Scholar]
  172. Taggart DP, Jenkins M, Hooper J, Hadjinikolas L, Kemp M. 171.  et al. 1996. Effects of short-term supplementation with coenzyme Q10 on myocardial protection during cardiac operations. Ann. Thorac. Surg. 61:829–33 [Google Scholar]
  173. Takahashi S, Ohtani T, Satoh H, Nakamura Y, Kawamukai M, Kadowaki K-I. 172.  2010. Development of coenzyme Q10-enriched rice using sugary and shrunken mutants. Biosci. Biotechnol. Biochem. 74:182–84 [Google Scholar]
  174. Takahashi T, Okuno M, Okamoto T, Kishi T. 173.  2008. NADPH-dependent coenzyme Q reductase is the main enzyme responsible for the reduction of non-mitochondrial CoQ in cells. Biofactors 32:59–70 [Google Scholar]
  175. Takimoto M, Sakurai T, Kodama K, Yokoi H, Suzuki Y. 174.  et al. 1982. Protective effect of CoQ10 administration on cardial toxicity in FAC therapy. Gan To Kagaku Ryoho 9:116–21 [Google Scholar]
  176. Tanaka J, Tominaga R, Yoshitoshi M, Matsui K, Komori M. 175.  et al. 1982. Coenzyme Q10: the prophylactic effect on low cardiac output following cardiac valve replacement. Ann. Thorac. Surg. 33:145–51 [Google Scholar]
  177. Taylor BA, Lorson L, White CM, Thompson PD. 176.  2015. A randomized trial of coenzyme Q10 in patients with confirmed statin myopathy. Atherosclerosis 238:329–35 [Google Scholar]
  178. Teclebrhan H, Olsson J, Swiezewska E, Dallner G. 177.  1993. Biosynthesis of the side chain of ubiquinone:trans-prenyltransferase in rat liver microsomes. J. Biol. Chem. 268:23081–86 [Google Scholar]
  179. Thelin A, Schedin S, Dallner G. 178.  1992. Half-life of ubiquinone-9 in rat tissues. FEBS Lett. 313:118–20 [Google Scholar]
  180. Tiano L, Belardinelli R, Carnevali P, Principi F, Seddaiu G, Littarru GP. 179.  2007. Effect of coenzyme Q10 administration on endothelial function and extracellular superoxide dismutase in patients with ischaemic heart disease: a double-blind, randomized controlled study. Eur. Heart J. 28:2249–55 [Google Scholar]
  181. Tomono Y, Hasegawa J, Seki T, Motegi K, Morishita N. 180.  1986. Pharmacokinetic study of deuterium-labelled coenzyme Q10 in man. Int. J. Clin. Pharmacol. Ther. Toxicol. 24:536–41 [Google Scholar]
  182. Tran UC, Clarke CF. 181.  2007. Endogenous synthesis of coenzyme Q in eukaryotes. Mitochondrion 7:S62–71 [Google Scholar]
  183. Usui T, Ishikura H, Izumi Y, Konishi H, Dohmae N. 182.  et al. 1982. Possible prevention from the progression of cardiotoxicity in adriamycin-treated rabbits by coenzyme Q10. Toxicol. Lett. 12:75–82 [Google Scholar]
  184. van Dalen EC, Caron HN, Dickinson HO, Kremer LC. 183.  2011. Cardioprotective interventions for cancer patients receiving anthracyclines. Cochrane Database Syst. Rev. 6:CD003917 [Google Scholar]
  185. van Heerebeek L, Hamdani N, Falcao-Pires I, Leite-Moreira AF, Begieneman MP. 184.  et al. 2012. Low myocardial protein kinase G activity in heart failure with preserved ejection fraction. Circulation 126:830–39 [Google Scholar]
  186. Vargiu R, Littarru GP, Faa G, Mancinelli R. 185.  2008. Positive inotropic effect of coenzyme Q10, omega-3 fatty acids and propionyl-L-carnitine on papillary muscle force-frequency responses of BIO TO-2 cardiomyopathic Syrian hamsters. Biofactors 32:135–44 [Google Scholar]
  187. Verma DD, Hartner WC, Thakkar V, Levchenko TS, Torchilin VP. 186.  2007. Protective effect of coenzyme Q10-loaded liposomes on the myocardium in rabbits with an acute experimental myocardial infarction. Pharm. Res. 24:2131–37 [Google Scholar]
  188. Villalba JM, Parrado C, Santos-Gonzalez M, Alcain FJ. 187.  2010. Therapeutic use of coenzyme Q10 and coenzyme Q10-related compounds and formulations. Expert Opin. Investig. Drugs 19:535–54 [Google Scholar]
  189. Watson PS, Scalia GM, Galbraith A, Burstow DJ, Bett N, Aroney CN. 188.  1999. Lack of effect of coenzyme Q on left ventricular function in patients with congestive heart failure. J. Am. Coll. Cardiol. 33:1549–52 [Google Scholar]
  190. Wilkinson EG, Arnold RM, Folkers K, Hansen I, Kishi H. 189.  1975. Bioenergetics in clinical medicine. II. Adjunctive treatment with coenzyme Q in periodontal therapy. Res. Commun. Chem. Pathol. Pharmacol. 12:111–23 [Google Scholar]
  191. Yamamoto Y, Yamashita S. 190.  1997. Plasma ratio of ubiquinol and ubiquinone as a marker of oxidative stress. Molec. Aspects Med. 18:s79–84 [Google Scholar]
  192. Yamamura Y. 191.  1977. Clinical status of coenzyme Q and prospects. Biomedical and Clinical Aspects of Coenzyme Q K Folkers, Y Yamamura 281–98 Amsterdam: Elsevier [Google Scholar]
  193. Yokoyama H, Lingle DM, Crestanello JA, Kamelgard J, Kott BR. 192.  et al. 1996. Coenzyme Q10 protects coronary endothelial function from ischemia reperfusion injury via an antioxidant effect. Surgery 120:189–96 [Google Scholar]
  194. Young JM, Florkowski CM, Molyneux SL, McEwan RG, Frampton CM. 193.  et al. 2007. Effect of coenzyme Q10 supplementation on simvastatin-induced myalgia. Am. J. Cardiol. 100:1400–3 [Google Scholar]
  195. Zhang Y, Aberg F, Appelkvist E-L, Dallner G, Ernster L. 194.  1995. Uptake of dietary coenzyme Q supplement is limited in rats. J. Nutr. 125:446–53 [Google Scholar]
  196. Zhang Y, Appelkvist E-L, Kristensson K, Dallner G. 195.  1996. The lipid compositions of different regions of rat brain during development and aging. Neurobiol. Aging 17:869–75 [Google Scholar]
  197. Zhang Y, Turunen M, Appelkvist E-L. 196.  1996. Restricted uptake of dietary coenzyme Q is in contrast to the unrestricted uptake of α-tocopherol into rat organs and cells. J. Nutr. 126:2089–97 [Google Scholar]
  198. Zhou M, Zhi Q, Tang Y, Yu D, Han J. 197.  1999. Effects of coenzyme Q10 on myocardial protection during cardiac valve replacement and scavenging free radical activity in vitro. J. Cardiovasc. Surg. (Torino) 40:355–61 [Google Scholar]
/content/journals/10.1146/annurev-nutr-071714-034258
Loading
/content/journals/10.1146/annurev-nutr-071714-034258
Loading

Data & Media loading...

  • Article Type: Review Article
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error